Stay up to date on tariff policies that impact your global operations. This section provides insights on trade developments, regulatory changes, and AdvaMed’s advocacy to minimize tariff burdens on medtech manufacturers and maintain global supply chain stability.
BOSTON—AdvaMed, the Medtech Association, concluded The MedTech Conference 2026, convening more than 4,470 attendees from 2,050 companies from 40 countries for the global medtech industry’s premier annual gathering.
Explore AdvaMed’s Q2 2026 Report to see how advocacy, member engagement, and policy progress are advancing innovation and strengthening the medtech industry.
After the Supreme Court struck down IEEPA tariffs, CBP launched the CAPE system to process refunds. Here’s what importers need to know about eligibility, submission, and timing.
Explore AdvaMed®’s Q1 2026 report on medtech policy, regulatory trends, reimbursement, and advocacy driving innovation and patient access.
The U.S. Supreme Court recently marked a significant shift in the tariff landscape, learn what that means for your organization.
Watch AdvaMed’s® exclusive member-only webinar featuring a direct dialogue with CMS Innovation Center leadership on the newly released ACCESS & TEMPO Model. Attendees will gain critical insights into model performance…
Scott Whitaker, president and CEO ofAdvaMed®, the world’s largest trade association representing medtech innovators, released the following statement after Fridays’ Supreme Court ruling on tariffs. Today, he published a more fulsome readout on LinkedIn, available here.
The U.S. Supreme Court recently marked a significant shift in the tariff landscape, learn what that means for your organization.
WASHINGTON—AdvaMed, the MedTech Association®, representing more than 650 medtech and health tech companies, the majority small businesses, today expressed support for renewal of the United States-Mexico-Canada Agreement (USMCA). Scott Whitaker,AdvaMed®…
As tariff uncertainty continues in 2025,AdvaMed® plays tariff chess, advocating for predictable, zero-for-zero policies to protect medtech innovation and access.